Unlocking the therapeutic potential of SLCs

Target opportunity

Solute carriers (SLCs) comprise more than 450 human membrane transporters that regulate fundamental cellular processes. Extensive human genetic evidence links SLCs to a broad range of diseases, while successful marketed medicines demonstrate their clinical and commercial potential. Yet, despite this strong validation, the vast majority of SLCs remain pharmacologically underexplored, representing a significant opportunity for first-in-class medicines.

Discovery challenge

The biggest barrier to unlocking SLCs is not their therapeutic relevance, but the difficulty of discovering molecules that effectively modulate their function. Their complex membrane biology, dynamic conformations, and limited availability of suitable screening assays make many SLCs inaccessible to conventional drug discovery approaches. As a result, even compelling, genetically validated targets often lack the chemical starting points needed to advance drug development.

Our platform

Solgate has built an integrated discovery platform designed specifically to overcome the challenges of SLC drug discovery. At its core is a versatile suite of functional, cell-based screening technologies that capture transporter biology in its native cellular context, enabling the identification of small molecules that conventional approaches may miss.

By integrating tailored functional assays with SLC-focused chemical matter, chemoproteomics, advanced cellular technologies, and medicinal chemistry, Solgate connects functional chemistry directly to functional transporter biology. This approach enables the exploration of diverse mechanisms, including inhibition, activation, allosteric modulation, protein correction, and protein–protein interaction disruption.

Our competitive edge lies in combining deep transporter biology with the ability to systematically discover and optimize functional SLC chemistry, opening new routes to drug targets that were previously inaccessible.

Therapeutic impact

The diversity of SLC biology creates compelling therapeutic opportunities across central nervous system disorders, kidney diseases, metabolic disorders, muscle diseases, and rare inherited metabolic conditions. Supported by human genetics and disease biology, these targets offer substantial potential for differentiated small-molecule therapies. Scientific and industry collaborations have provided validation of Solgate’s discovery approach to extend its application across therapeutic areas.

References

Superti-Furga G et al. Nature Reviews Drug Discovery (2020). The RESOLUTE consortium: unlocking SLC transporters for drug discovery. Read publication

Lin L et al. Nature Reviews Drug Discovery (2015). SLC transporters as therapeutic targets: emerging opportunities. Read publication

Law YK et al. Nature Reviews Drug Discovery (2026). Solute carrier membrane transporters: emerging targets in CNS disorders. Read publication